目的 通过比较铂类及其他抗肿瘤药物的应用情况,了解铂类各代药物在抗肿瘤治疗中的应用情况及发展趋势,为铂类药物的应用前景提供数据支持.方法 对2011年-2017年我院铂类药物与其他抗肿瘤药物的使用情况进行比较,并统计各代铂类药物(顺铂、卡铂、奈达铂及奥沙利铂)的使用情况,内容包括药物的处方量、用药总金额、约定日剂量(DDD)、用药频度(DDDs)、限定日费用(DDC)、药物利用指数(DUI)等.结果 铂类药物的处方量及DDDs在9种抗肿瘤药物中占比最高,分别为27.56% 和31.68%,而DDC占比仅1.15%.主动靶向药物的DDC最高,为23 848.91元,占比61.77%.在铂类药物中,处方量及DDDs占比最高的是顺铂,分别为61.39%和64.10%;DDC最高的是进口奥沙利铂,达7935.41元.各铂类药物的DUI均接近1.0.结论 本院铂类药物的使用基本合理,顺铂在抗肿瘤药物中的使用量最高.铂类药物在抗肿瘤治疗中仍占主导地位并保持上升趋势,新型靶向药物的使用量亦呈逐渐增长趋势.%Objective To understand the application and tendency of platinum drugs in antitumor therapy and provide data support for the platinum drug prospect, according to the comparison of the application of the platinum and other antitumor drugs. Methods A retrospective analysis was implemented on the application of the platinum and other antitumor drugs from 2011 to 2017 in the Cancer Hospital of Shantou University Medical College. The data were calculated, including the quantity of prescriptions, total consumption, defined daily dose (DDD), de-fined daily doses (DDDs), defined daily cost (DDC) and drug utilization index (DUI) of platinum drugs (Cis-platinum, Carboplatin, Nedaplatin and Oxaliplatin) and other antitumor drugs. Results The platinum accounted for 27.56% and 31.68% for the total prescriptions and DDDs in all antitumor drugs, but only 1.15% for DDC. The DDC of the actively targeting drugs ranked first, 23848.91 Yuan, with a proportion of 61.77% in all antitumor drugs. Cis-platinum ranked first with the proportion as 61.39% for prescription and 64.10% for DDDs, in all platinum drugs. The DDC of imported Oxaliplatin ranked first, up to 7935.41 Yuan. The DUI of all platinum drugs was close to 1.0. Conclusion The usage of platinum was basically appropriate. Cis-platinum took the largest amount in usage. The platinum drugs still take an important role in anti-tumor therapy and keep an increasing tendency in usage. Novel targeted drugs is also gradually increasing in application.
展开▼
